CL King Has Started Coverage on Bio-Rad Labs (NYSE:BIO) Stock with Buy Rating

Share with your friends


NewYork Bio-Rad Labs NYSE:BIO

Bio-Rad Labs (NYSE:BIO) New Coverage by CL King

New York: Bio-Rad Labs (NYSE:BIO) coverage was started with a Buy rating by equity analysts at CL King. This was shared with investors and clients in a note on Thursday, 13 October.

In spite of the new coverage NYSE:BIO is at the moment trading -0.44% lower at $161.06 as of 04:00 New York time. Bio-Rad Labs shares have risen 14.99% in the past 200 days, while the S&P 500 has increased 4.02% in the same time.

NYSE:BIO Price Chart & Trend

The stock price of Bio-Rad Labs went up 14.99% over the last 200 days, and is in strong up trend. In the last 50 and 100 days, Bio-Rad Labs is up 10.28% and up 11.57%, respectively. Our stocks momentum model is shown on the price chart below.CL King Has Started Coverage on Bio-Rad Labs (NYSE:BIO) Stock with Buy Rating

Source: RightEdge Systems, Yahoo Split & Dividend Adjusted Data and OctaFinance Trading Models

Institutional Ownership

Tikvah Management Llc had the most significant stake with ownership of 109,107 shares as of Q2 2015 for 8.72% of the portfolio. Intrepid Capital Management Inc is another quite bullish investment professional who is possessing 87,545 shares of Bio-Rad Labs or 4.33% of their portfolio. In addition, Sector Gamma As have 4.05% of their portfolio invested in the company for 105,400 shares. The California-based fund Tamarack Capital Management Llc revealed it had bought a stake worth about 2.1% of the investment professional’s stock portfolio in Bio-Rad Labs. The Massachusetts-based fund Copper Rock Capital Partners Llc is also positive about the stock, possessing 121,050 shares or 1.99% of their portfolio.

Bio-Rad Labs (NYSE:BIO) Profile

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics.

Bio-Rad Labs (NYSE:BIO) traded down -0.44% on 13 October, hitting $161.06. A total of 129,822 shares of the company’s stock traded hands. This is down from average of 136,119 shares. Bio-Rad Labs has a 52 week low of $122.03 and a 52 week high of $164.89. The company has a market cap of $4.67 billion and a P/E ratio of 48.94.

Get the latest Bio-Rad Labs (NYSE:BIO) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

Bio-Rad Labs - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.